Introduction to Revised Criteria for the Diagnosis of Alzheimer’s Disease: National Institute on Aging and the Alzheimer Association Workgroups

By Clifford R. Jack Jr., Marilyn S. Albert, David S. Knopman, Guy M. McKhann, Reisa A. Sperling, M. Carillo, William H. Thies, C. Phelps. Alzheimer's & Dementia, 2011

1,981 citations recorded by the source corpus.

Criteria for the clinical diagnosis of Alzheimer's disease (AD) were established in 1984. A broad consensus now exists that these criteria should be revised to incorporate state‐of‐the‐art scientific knowledge.

Subfields: Molecular Biology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/da827ffb6cde4ba18fb5b76029fbf39b6234b957

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Physiology

In Psychiatry and Mental health

Citations in the corpus

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease (2014, background): “The US National Institute on Aging-Alzheimer’s Association (NIA-AA) group proposed (1) the preclinical stage of AD (no impairment in cognition on standard assessments and biomarker evidence for AD), (2) mild cognitive impairment (MCI) due to AD (impairment on memory or other domains of cognition on ”
Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria (2016, background): “It has been proposed that the presence of at least one marker of brain amyloidosis in CSF or PET in cognitively normal individuals may be sufficient to establish the diagnosis of AD, even in the absence of any clinical manifestations [21,23,24].”
What is normal in normal aging? Effects of Aging, Amyloid and Alzheimer’s Disease on the Cerebral Cortex and the Hippocampus (2014, background): “…amyloid in AD, as for instance reflected in the proposed diagnostic guidelines from the National Institute of Aging – Alzheimer’s Association (NIA-AA) (Jack et al., 2011; Sperling et al., 2011a) and the popular ‘dynamic biomarker model’ (Jack et al., 2010a, 2013), suggest that the influence of…”
Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial (2016, methodology): “The AD patients were diagnosed following the NINDS-ADRDA criteria (McKhann et al., 1984) and revised criteria from the National Institute on Aging-Alzheimer’s Association (Jack et al., 2011).”
Impact of multiple pathologies on the threshold for clinically overt dementia (2017, background): “Lack of a concise and sensitive cognitive biomarker of AD has led to the widespread use of ancillary testing, particularly CSF and imaging markers, which have been codified into a number of recent diagnostic guidelines [34, 52].”
Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: the CADDementia challenge (2015, methodology): “As reference standard for evaluation of the algorithms, the current clinical diagnosis criteria for AD (McKhann et al., 2011) and MCI (Petersen, 2004) were used, which is a common practice in studies of computer-aided diagnosis methods (Cuingnet et al., 2011; Klöppel et al., 2008; Falahati et al.,…”
The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease (2011, neutral): “Details of the selection and the charge to the working group are outlined in the Introduction to the revised criteria for AD that accompanies this article [1].”
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease (2011, background): “The rationale for including biomarkers for the pathophysiological process of AD in the diagnostic criteria is summarized in the Introduction to this series of articles [3], The major AD biomarkers that have been widely investigated at this time (see [21] for review) may be broken into two classes ba”
Alzheimer's disease diagnostics by adaptation of 3D convolutional network (2016, background): “Several popular non-invasive neuroimaging tools, such as structural MRI (sMRI), functional MRI (fMRI), and positron emission tomography (PET), have been investigated for developing such a system [4, 5].”
Alzheimer’s disease: experimental models and reality (2017, background): “The clinical diagnosis of AD is currently based on decline in specific areas of cognition and a positive result on AD biomarker assays including amyloid and/or tau PET; as well as, Aβ and tau levels in the CSF, which directly or indirectly reflect the changes that are used for the neuropathological ”